FDA advisers narrowly vote in favor of Sarepta's DMD gene therapy

FDA advisers have narrowly voted in favor of Sarepta Therapeutics' gene therapy for patients with Duchenne muscular dystrophy (DMD), a stunning decision that runs counter to regulators who expressed skepticism heading into the meeting.